Contactez nous

Eurobio Oncologie

EndoPredict: Case studies

Prof. Dr. med. Michael Untch, Head of Clinic for Gynecology, Gynecologic Oncology and Obstetrics, Head of Breast Interdisciplinary Cancer Center Department of Obstetrics and Gynecology, HELIOS Clinic Berlin-Buch in Berlin, Germany

Watch Prof. Untch’s Case Study

  • 43 years old, premenopausal, pT1c, N0, G2, L0, V0, R0, ER 100%, HER2-, PR 100%, Ki67 15%, early-stage breast cancer patient
  • Poll of other clinicians’ case opinions
  • How her EndoPredict result supported a confident treatment decision
  • Clinical validation of the test in this patient group
Watch Now

Get Clear Results

Based on her individualized risk score. See her full report

0 %

Risk of distant recurrence within 10 years

0 %

Absolute individualized chemotherapy benefit

0 %

5–15 year late distant recurrence risk*

*with 5 years of endocrine therapy alone

Full Report

Have Informed Conversations

EndoPredict results are simple to understand and straightforward to explain.

For this case, you could say:

  • Your EndoPredict result indicates that your cancer is unlikely to come back in other parts of your body.
  • This result takes into account both your tumor’s gene activity and clinical information, giving a personalized view of your situation.
  • It suggests there is a 92% probability that your cancer will not return within the next 10 years.
  • Chemotherapy could slightly improve this probability by about 2%, but for many patients, the small benefit may not justify the potential side effects.

Make Confident Decisions Knowing Her Result

  • Comes from the most advanced, second-generation prognostic and predictive test1,2
  • Combines clinical factors with molecular insights from genes linked to early and late recurrence.3-4
  • Is clinically validated and prospectively confirmed in both post- and premenopausal patients.1-10
  • Provides long-term insight, including distant-recurrence information up to 15 years, to support treatment planning.5
  • Comes from a test recommended in the ESMO guidelines with Level of Evidence 1A.11

What it Meant for this Patient

Her report breakdown

Based on her clear EndoPredict result, the patient and her clinician decided to proceed without chemotherapy – avoiding unnecessary side effects while feeling confident in her favorable long-term outlook.

  1. Sestak I. et al : Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018
  2. Sestak I. et al : Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019
  3. Filipits M. et al : A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors (Un nouveau prédicteur moléculaire de récidive à distance dans le cancer du sein ER-Positif, HER2-Negatif ajoute des informations indépendantes aux facteurs de risque cliniques conventionnels). Clin. Cancer Res. 2011
  4. Dubsky P. et al.: EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013; 24:640-647
  5. Filipits M. et al : Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019
  6. Constantinidou A. et al : Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer (Validation clinique d'EndoPredict chez des femmes pré-ménopausées atteintes d'un cancer du sein primaire ER positif, HER2 négatif). Clin. Cancer Res. 2022
  7. Buus R. et al : Comparaison d'EndoPredict et d'EPclin avec le score de récidive d'Oncotype DX pour la prédiction du risque de récidive à distance après une thérapie endocrinienne. J Natl Cancer Inst. 2016
  8. Klein, E. et al : Long-term outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor positive, HER2-negative early breast cancer. Breast Cancer Res Treat. 2024
  9. Schmitt, W. D. et al : Évaluation rétrospective des résultats dans un monde réel, cohorte prospective utilisant EndoPredict : Résultats du registre de la Charité. SABCS 2022
  10. Vázquez-Juarez D. et al : Suivi d'une cohorte prospective de femmes mexicaines préménopausées atteintes d'un cancer du sein et ayant reçu un traitement adjuvant guidé par le test EndoPredict. SABCS 2021
  11. Loibl S. et al.: Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023
Prof. Dr. med. Michael Untch, Head of Clinic for Gynecology, Gynecologic Oncology and Obstetrics, Head of Breast Interdisciplinary Cancer Center Department of Obstetrics and Gynecology, HELIOS Clinic Berlin-Buch in Berlin, Germany

Watch Prof. Untch’s Case Study

  • 50 years old, postmenopausal, pT2, N1, G2, L0, V0, R0, ER 30/80%, PR 100/90%, Ki67 10%, lobular early-stage breast cancer patient
  • Poll of other clinicians’ case opinions
  • How her EndoPredict result changed the treatment decision
  • Clinical validation of the test in this patient group
Watch Now

Get Clear Results

Based on her individualized risk score. See her full report

0 %

Risk of distant recurrence within 10 years

0 %

Absolute individualized chemotherapy benefit

0 %

5–15 year late distant recurrence risk*

*with 5 years of endocrine therapy alone

Full Report

Have Informed Conversations

EndoPredict results are simple to understand and straightforward to explain.

For this case, you could say:

  • Your EndoPredict result shows that your cancer is at low-risk of coming back in other parts of your body.
  • The result combines information from your tumor’s gene activity and clinical factors to give a clear picture of your situation.
  • Based on this, there is a 91% chance your cancer will not return within 10 years.
  • Adding chemotherapy could increase this chance by 3%, but the small potential benefit may not outweigh the possible side effects.

Make Confident Decisions Knowing Her Result

  • Comes from the most advanced, second-generation prognostic and predictive test.1,2
  • Combines clinical factors with molecular insights from genes linked to early and late recurrence.3-4
  • Is clinically validated and prospectively confirmed in both post- and premenopausal patients.1-10
  • Provides long-term insight, including distant-recurrence information up to 15 years, to support treatment planning.5
  • Comes from a test recommended in the ESMO guidelines with Level of Evidence 1A.11

What it Meant for this Patient

Guidés par ce résultat, la patiente et son clinicien ont choisi de poursuivre le traitement sans chimiothérapie, lui épargnant ainsi des effets secondaires potentiels et leur donnant confiance dans son plan de traitement.

Her report breakdown
  1. Sestak I. et al : Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018
  2. Sestak I. et al : Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019
  3. Filipits M. et al : A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors (Un nouveau prédicteur moléculaire de récidive à distance dans le cancer du sein ER-Positif, HER2-Negatif ajoute des informations indépendantes aux facteurs de risque cliniques conventionnels). Clin. Cancer Res. 2011
  4. Dubsky P. et al.: EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013; 24:640-647
  5. Filipits M. et al : Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019
  6. Constantinidou A. et al : Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer (Validation clinique d'EndoPredict chez des femmes pré-ménopausées atteintes d'un cancer du sein primaire ER positif, HER2 négatif). Clin. Cancer Res. 2022
  7. Buus R. et al : Comparaison d'EndoPredict et d'EPclin avec le score de récidive d'Oncotype DX pour la prédiction du risque de récidive à distance après une thérapie endocrinienne. J Natl Cancer Inst. 2016
  8. Klein, E. et al : Long-term outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor positive, HER2-negative early breast cancer. Breast Cancer Res Treat. 2024
  9. Schmitt, W. D. et al : Évaluation rétrospective des résultats dans un monde réel, cohorte prospective utilisant EndoPredict : Résultats du registre de la Charité. SABCS 2022
  10. Vázquez-Juarez D. et al : Suivi d'une cohorte prospective de femmes mexicaines préménopausées atteintes d'un cancer du sein et ayant reçu un traitement adjuvant guidé par le test EndoPredict. SABCS 2021
  11. Loibl S. et al : Early breast cancer : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023
Prof. Dr. med. Michael Untch, Head of Clinic for Gynecology, Gynecologic Oncology and Obstetrics, Head of Breast Interdisciplinary Cancer Center Department of Obstetrics and Gynecology, HELIOS Clinic Berlin-Buch in Berlin, Germany

Watch Prof. Untch’s Case Study

  • 68 ans, pT1b (9 mm), N0, G2, L0, V0, PN0, R0, ER 100%, PR 15%, Ki67 40% patiente atteinte d'un cancer du sein au stade précoce
  • Poll of other clinicians’ case opinions
  • How her EndoPredict result changed the treatment decision
  • Clinical validation of the test in this patient group
Watch Now

Obtenir des résultats clairs

Based on her individualized risk score. See her full report

0 %

Risk of distant recurrence within 10 years

0 %

Absolute individualized chemotherapy benefit

0 %

5–15 year late distant recurrence risk*

*with 5 years of endocrine therapy alone

Full Report

Have Informed Conversations

EndoPredict results are simple to understand and straightforward to explain.

For this case, you could say:

  • Votre résultat EndoPredict indique un score de risque élevé.
  • Cela signifie que, sur la base des gènes de votre tumeur et d'autres facteurs cliniques, il y a 19% de chances que votre cancer réapparaisse dans les 10 ans, soit environ 1 patient sur 5.
  • La chimiothérapie peut réduire ce risque d'environ 8%, le ramenant à environ 1 sur 13, ce qui peut contribuer à améliorer vos perspectives à long terme.

Make Confident Decisions Knowing Her Result

  • Comes from the most advanced, second-generation prognostic and predictive test.1,2
  • Combines clinical factors with molecular insights from genes linked to early and late recurrence.3-4
  • Is clinically validated and prospectively confirmed in both post- and premenopausal patients.1-10
  • Provides long-term insight, including distant-recurrence information up to 15 years, to support treatment planning.5
  • Comes from a test recommended in the ESMO guidelines with Level of Evidence 1A.11

What it Meant for this Patient

Sur la base de ce résultat clair, cette patiente et son clinicien ont décidé d'ajouter une chimiothérapie adjuvante à son plan de traitement. Ils ont pu faire ce choix en toute confiance, sachant que même si la chimiothérapie peut être difficile, elle réduira considérablement le risque de récidive.

Her report breakdown
  1. Sestak I. et al : Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018
  2. Sestak I. et al : Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019
  3. Filipits M. et al : A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors (Un nouveau prédicteur moléculaire de récidive à distance dans le cancer du sein ER-Positif, HER2-Negatif ajoute des informations indépendantes aux facteurs de risque cliniques conventionnels). Clin. Cancer Res. 2011
  4. Dubsky P. et al.: EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013; 24:640-647
  5. Filipits M. et al : Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019
  6. Constantinidou A. et al : Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer (Validation clinique d'EndoPredict chez des femmes pré-ménopausées atteintes d'un cancer du sein primaire ER positif, HER2 négatif). Clin. Cancer Res. 2022
  7. Buus R. et al : Comparaison d'EndoPredict et d'EPclin avec le score de récidive d'Oncotype DX pour la prédiction du risque de récidive à distance après une thérapie endocrinienne. J Natl Cancer Inst. 2016
  8. Klein, E. et al : Long-term outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor positive, HER2-negative early breast cancer. Breast Cancer Res Treat. 2024
  9. Schmitt, W. D. et al : Évaluation rétrospective des résultats dans un monde réel, cohorte prospective utilisant EndoPredict : Résultats du registre de la Charité. SABCS 2022
  10. Vázquez-Juarez D. et al : Suivi d'une cohorte prospective de femmes mexicaines préménopausées atteintes d'un cancer du sein et ayant reçu un traitement adjuvant guidé par le test EndoPredict. SABCS 2021
  11. Loibl S. et al : Early breast cancer : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023

Recherche

Retour en haut